Noncanonical mechanisms to regulate nuclear receptor signaling

Future Medicinal Chemistry

Volumn 4, Issue 10, 2012, Pages 1307-1333

  Sadana, Prabodh ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; 5 ALLYL 1,2 DIHYDRO 10 METHOXY 2,2,4 TRIMETHYL 5H 1 BENZOPYRANO[3,4 F]QUINOLINE; ACP 105; BAZEDOXIFENE; BMS 564929; CALCITRIOL; CELL NUCLEUS RECEPTOR; DEXAMETHASONE; FENOFIBRATE; FLUTAMIDE; FLUTICASONE; HORMONE RECEPTOR AFFECTING AGENT; LASOFOXIFENE; LEVOTHYROXINE; MEGESTROL ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PREDNISOLONE; RALOXIFENE; RU 24858; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELECTIVE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SPIRONOLACTONE; TAMOXIFEN; TFM 4 AS 1; TOREMIFENE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; DNA BINDING; DOWN REGULATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; INTRACELLULAR SIGNALING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW;

DNA; DRUG EVALUATION, PRECLINICAL; HUMANS; LIGANDS; MICRORNAS; PEPTIDES; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84863963911     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.72     Document Type: Review

References (193)

1. Mangelsdorf DJ, Thummel C, Beato M et al. The nuclear receptor superfamily. The second decade. Cell 83(6), 835-839 (1995).
2. Nuclear Receptors Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell 97(2), 161-163 (1999).
3. Mcewan IJ. Nuclear receptors. One big family. Methods Mol. Biol. 505, 3-18 (2009).
4. Wrange O, Gustafsson JA. Separation of the hormone- and DNA-Binding sites of the hepatic glucocorticoid receptor by means of proteolysis. J. Biol. Chem. 253(3), 856-865 (1978).
5. Green S, Chambon P. Oestradiol induction of a glucocorticoid-Responsive gene by a chimaeric receptor. Nature 325(6099), 75-78 (1987).
6. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 240(4854), 889-895 (1988).
7. Wurtz JM, Bourguet W, Renaud JP et al. A canonical structure for the ligand-Binding domain of nuclear receptors. Nat. Struct. Biol. 3(1), 87-94 (1996).
8. Huang P, Chandra V, Rastinejad F. Structural overview of the nuclear receptor superfamily. insights into physiology and therapeutics. Annu. Rev. Physiol. 72, 247-272.
9. Li Y, Lambert MH, Xu HE. Activation of nuclear receptors. a perspective from structural genomics. Structure 11(7), 741-746 (2003).
10. Nagy L, Schwabe JW. Mechanism of the nuclear receptor molecular switch. Trends Biochem. Sci. 29(6), 317-324 (2004).
11. Khorasanizadeh S, Rastinejad F. Nuclear-Receptor interactions on DNA-Response elements. Trends Biochem Sci 26(6), 384-390 (2001).
12. Mader S, Chen JY, Chen Z, White J, Chambon P, Gronemeyer H. The patterns of binding of RAR, RXR and TR homo- and heterodimers to direct repeats are dictated by the binding specificites of the DNA binding domains. EMBO J 12(13), 5029-5041 (1993).
13. Umesono K, Murakami KK, Thompson CC, Evans RM. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65(7), 1255-1266 (1991).
14. Rastinejad F, Perlmann T, Evans RM, Sigler PB. Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature 375(6528), 203-211 (1995).
15. Glass CK. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr. Rev. 15(3), 391-407 (1994).
16. Meinke G, Sigler PB. DNA-Binding mechanism of the monomeric orphan nuclear receptor NGFI-B. Nat. Struct. Biol. 6(5), 471-477 (1999).
17. Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals. a coactivator/corepressor/ epigenetic code for integrating signal-Dependent programs of transcriptional response. Genes Dev. 20(11), 1405-1428 (2006).
18. Aoyagi S, Archer TK. Dynamics of coactivator recruitment and chromatin modifications during nuclear receptor mediated transcription. Mol. Cell. Endocrinol. 280(1-2), 1-5 (2008).
19. Lee JW, Choi HS, Gyuris J, Brent R, Moore DD. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol. Endocrinol. 9(2), 243-254 (1995).
20. Fondell JD, Ge H, Roeder RG. Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proc. Natl Acad. Sci. USA 93(16), 8329-8333 (1996).
21. Lonard DM, O'Malley BW. Nuclear receptor coregulators. Judges, juries, and executioners of cellular regulation. Mol. Cell 27(5), 691-700 (2007).
22. Smith CL, O'Malley BW. Coregulator function. a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25(1), 45-71 (2004).
23. Han SJ, Lonard DM, O'Malley BW. Multi-Modulation of nuclear receptor coactivators through posttranslational modifications. Trends Endocrinol. Metab. 20(1), 8-15 (2009).
24. Hopkins AL, Groom CR. The druggable genome. Nat. Rev. Drug Discov. 1(9), 727-730 (2002).
25. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3(11), 950-964 (2004).
26. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D. Crystal structure of the ligand-Binding domain of the human nuclear receptor RXR-Alpha. Nature 375(6530), 377-382 (1995).
27. Renaud JP, Rochel N, Ruff M et al. Crystal structure of the RAR-Gamma ligand-Binding domain bound to all-Trans retinoic acid. Nature 378(6558), 681-689 (1995).
28. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J. Biol. Chem. 273(47), 31108-31112 (1998).
29. Williams SP, Sigler PB. Atomic structure of progesterone complexed with its receptor. Nature 393(6683), 392-396 (1998).
30. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell 5(1), 173-179 (2000).
31. Chandra V, Huang P, Hamuro Y et al. Structure of the intact PPAR-Gamma-RXR-Alpha nuclear receptor complex on DNA. Nature 350-356 (2008).
32. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324(5925), 407-410 (2009).
33. Watkins RE, Maglich JM, Moore LB et al. 2.1 Å crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 42(6), 1430-1438 (2003).
34. Chrencik JE, Orans J, Moore LB et al. Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol. Endocrinol. 19(5), 1125-1134 (2005).
35. Watkins RE, Wisely GB, Moore LB et al. The human nuclear xenobiotic receptor PXR. structural determinants of directed promiscuity. Science 292(5525), 2329-2333 (2001).
36. Chen CN, Shih YH, Ding YL, Leong MK. Predicting activation of the promiscuous human pregnane X receptor by pharmacophore ensemble/support vector machine approach. Chem. Res. Toxicol. 24(10), 1765-1778 (2011).
37. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl J. Med. 353(16), 1711-1723 (2005).
38. Noller KL. Estrogen replacement therapy and risk of ovarian cancer. JAMA 288(3), 368-369 (2002).
39. Beral V. Breast cancer and hormone-Replacement therapy in the Million Women Study. Lancet 362(9382), 419-427 (2003).
40. Black LJ, Sato M, Rowley ER et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93(1), 63-69 (1994).
41. Labrie F. Drug insight. breast cancer prevention and tissue-Targeted hormone replacement therapy. Nat. Clin. Pract. Endocrinol. Metab. 3(8), 584-593 (2007).
42. Nilsson S, Koehler KF, Gustafsson JA. Development of subtype-Selective oestrogen receptor-Based therapeutics. Nat. Rev. Drug Discov. 10(10), 778-792
43. Newton R, Holden NS. Separating transrepression and transactivation. A distressing divorce for the glucocorticoid receptor? Mol. Pharmacol. 72(4), 799-809 (2007).
44. Imai E, Miner JN, Mitchell JA, Yamamoto KR, Granner DK. Glucocorticoid receptor-CAMP response element-Binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids. J. Biol. Chem. 268(8), 5353-5356 (1993).
45. Ming M, Chan W, Wang TT et al. Beta-Adrenoceptors and dexamethasone synergistically stimulate the expression of the angiotensinogen gene in opossum kidney cells. Kidney Int. 50(1), 94-101 (1996).
46. Nguyen TD, Chen P, Huang WD, Chen H, Johnson D, Polansky JR. Gene structure and properties of TIGR, an olfactomedin-Related glycoprotein cloned from glucocorticoid-Induced trabecular meshwork cells. J. Biol. Chem. 273(11), 6341-6350 (1998).
47. Jantzen HM, Strahle U, Gloss B et al. Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene. Cell 49(1), 29-38 (1987).
48. Morrison N, Eisman J. Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J. Bone Miner. Res. 8(8), 969-975 (1993).
49. Vayssiere BM, Dupont S, Choquart A et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol. Endocrinol. 11(9), 1245-1255 (1997).
50. Chen T. Nuclear receptor drug discovery. Curr. Opin. Chem. Biol. 12(4), 418-426 (2008).
51. Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs). Novel ligands with an improved therapeutic index. Mol. Cell. Endocrinol. 275(1-2), 109-117 (2007).
52. Schacke H, Schottelius A, Docke WD et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl Acad. Sci. USA 101(1), 227-232 (2004).
53. Coghlan MJ, Jacobson PB, Lane B et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol. Endocrinol. 17(5), 860-869 (2003).
54. Miner JN, Tyree C, Hu J et al. A nonsteroidal glucocorticoid receptor antagonist. Mol. Endocrinol. 17(1), 117-127 (2003).
55. Owen HC, Miner JN, Ahmed SF, Farquharson C. The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol. Cell. Endocrinol. 264(1-2), 164-170 (2007).
56. Humphrey EL, Williams JH, Davie MW, Marshall MJ. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 38(5), 652-661 (2006).
57. Morgan BP, Swick AG, Hargrove DM et al. Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J. Med. Chem. 45(12), 2417-2424 (2002).
58. Robinson RP, Buckbinder L, Haugeto AI et al. Octahydrophenanthrene-2,7- Diol analogues as dissociated glucocorticoid receptor agonists. discovery and lead exploration. J. Med. Chem. 52(6), 1731-1743 (2009).
59. Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov. Today 12(5-6), 241-248 (2007).
60. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl Cancer. Inst. 88(16), 1118-1126 (1996).
61. Holmang S, Marin P, Lindstedt G, Hedelin H. Effect of long-Term oral testosterone undecanoate treatment on prostate volume and serum prostate-Specific antigen concentration in eugonadal middle-Aged men. Prostate 23(2), 99-106 (1993).
62. Vermeulen A. Androgen replacement therapy in the aging male-A critical evaluation. J. Clin. Endocrinol. Metab. 86(6), 2380-2390 (2001).
63. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J. Androl. 15(3), 212-215 (1994).
64. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Selective androgen receptor modulators in preclinical and clinical development. Nucl. Recept. Signal. 6, e010 (2008).
65. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD. Discovery of nonsteroidal androgens. Biochem. Biophys. Res. Commun. 244(1), 1-4 (1998).
66. Edwards JP, West SJ, Pooley CL, Marschke KB, Farmer LJ, Jones TK. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)- Pyrrolidino[3,2-G] quinolinone. Bioorg. Med. Chem. Lett. 8(7), 745-750 (1998).
67. Yin D, Gao W, Kearbey JD et al. Pharmacodynamics of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. 304(3), 1334-1340 (2003).
68. Chen J, Hwang DJ, Bohl CE, Miller DD, Dalton JT. A selective androgen receptor modulator for hormonal male contraception. J. Pharmacol. Exp. Ther. 312(2), 546-553 (2005).
69. Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT. Preclinical characterization of a (S)-N-(4-Cyano-3-Trifluoromethyl-Phenyl)-3- (3-Fluoro, 4-Chlorophenoxy)-2-Hydroxy-2- methyl-Propanamide. A selective androgen receptor modulator for hormonal male contraception. Endocrinology 150(1), 385-395 (2009).
70. Schlienger N, Lund BW, Pawlas J et al. Synthesis, structure-Activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators. J. Med. Chem. 52(22), 7186-7191 (2009).
71. Schmidt A, Harada S, Kimmel DB et al. Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J. Biol. Chem. 284(52), 36367-36376 (2009).
72. Ostrowski J, Kuhns JE, Lupisella JA et al. Pharmacological and x-Ray structural characterization of a novel selective androgen receptor modulator. Potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 148(1), 4-12 (2007).
73. Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, Dalton JT. Steroidal androgens and nonsteroidal, tissue-Selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol. Endocrinol. 22(11), 2448-2465 (2008).
74. Russell DW, Wilson JD. Steroid 5 alpha-Reductase. Two genes/two enzymes. Annu. Rev. Biochem. 63, 25-61 (1994).
75. Motani A, Wang Z, Weiszmann J et al. INT131. A selective modulator of PPAR gamma. J Mol Biol 386(5), 1301-1311 (2009).
76. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-Modulating activity. Hypertension 43(5), 993-1002 (2004).
77. Schupp M, Clemenz M, Gineste R et al. Molecular characterization of new selective peroxisome proliferator-Activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54(12), 3442-3452 (2005).
78. Tagami T, Yamamoto H, Moriyama K et al. A selective peroxisome proliferator-Activated receptor-Gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology 150(2), 862-870 (2009).
79. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-Induced obese mice. Hypertension 48(1), 51-57 (2006).
80. Allen T, Zhang F, Moodie SA et al. Halofenate is a selective peroxisome proliferator-Activated receptor gamma modulator with antidiabetic activity. Diabetes 55(9), 2523-2533 (2006).
81. Chang CH, Mcnamara LA, Wu Ms et al. A novel selective peroxisome proliferator-Activator receptor-Gamma modulator- SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects. Eur. J. Pharmacol. 584(1), 192-201 (2008).
82. Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr. Pharm. Des. 10(22), 2779-2786 (2004).
83. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-Activated receptor-Gamma is a negative regulator of macrophage activation. Nature 391(6662), 79-82 (1998).
84. Straus DS, Pascual G, Li M et al. 15-Deoxy-Delta 12,14-Prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc. Natl Acad. Sci. USA 97(9), 4844-4849 (2000).
85. Tancevski I, Rudling M, Eller P. Thyromimetics. A journey from bench to bed-Side. Pharmacol. Ther. 131(1), 33-39 (2011).
86. Yoshihara HA, Scanlan TS. Selective thyroid hormone receptor modulators. Curr. Top. Med. Chem. 3(14), 1601-1616 (2003).
87. Trost SU, Swanson E, Gloss B et al. The thyroid hormone receptor-Beta-Selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 141(9), 3057-3064 (2000).
88. Grover GJ, Mellstrom K, Ye L et al. Selective thyroid hormone receptor-Beta activation. a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc. Natl Acad. Sci. USA 100(17), 10067-10072 (2003).
89. Ye L, Li YL, Mellstrom K et al. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. J. Med. Chem. 46(9), 1580-1588 (2003).
90. Alberti S, Steffensen KR, Gustafsson JA. Structural characterisation of the mouse nuclear oxysterol receptor genes LXRalpha and LXRbeta. Gene 243(1-2), 93-103 (2000).
91. Wrobel J, Steffan R, Bowen SM et al. Indazole-Based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. J. Med. Chem. 51(22), 7161-7168 (2008).
92. Hu B, Unwalla RJ, Goljer I et al. Identification of phenylsulfone- Substituted quinoxaline (WYE-672) as a tissue selective liver X-Receptor (LXR) agonist. J. Med. Chem. 53(8), 3296-3304 (2010).
93. Lonard Dm, Lanz RB, O'Malley BW. Nuclear receptor coregulators and human disease. Endocr. Rev. 28(5), 575-587 (2007).
94. Spencer TE, Jenster G, Burcin MM et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389(6647), 194-198 (1997).
95. Rodriguez AL, Tamrazi A, Collins ML, Katzenellenbogen JA. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding. J. Med. Chem. 47(3), 600-611 (2004).
96. Parent AA, Gunther JR, Katzenellenbogen JA. Blocking estrogen signaling after the hormone. Pyrimidine-Core inhibitors of estrogen receptor-Coactivator binding. J. Med. Chem. 51(20), 6512-6530 (2008).
97. Shao D, Berrodin TJ, Manas E et al. Identification of novel estrogen receptor alpha antagonists. J. Steroid Biochem. Mol. Biol. 88(4-5), 351-360 (2004).
98. Gunther JR, Parent AA, Katzenellenbogen JA. Alternative inhibition of androgen receptor signaling. Peptidomimetic pyrimidines as direct androgen receptor/ coactivator disruptors. ACS Chem. Biol. 4(6), 435-440 (2009).
99. Arnold LA, Estebanez-Perpina E, Togashi M et al. Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J. Biol. Chem. 280(52), 43048-43055 (2005).
100. Hwang JY, Arnold LA, Zhu F et al. Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J. Med. Chem. 52(13), 3892-3901 (2009)
101. Sadana P, Hwang JY, Attia RR, Arnold LA, Neale G, Guy RK. Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem. Biol. 6(10), 1096-1106
102. Hwang JY, Huang W, Arnold LA et al. Methylsulfonylnitrobenzoates, a new class of irreversible inhibitors of the interaction of the thyroid hormone receptor and its obligate coactivators that functionally antagonizes thyroid hormone. J. Biol. Chem. 286(14), 11895-11908 (2011).
103. Wang H, Li H, Moore LB et al. The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol. Endocrinol. 22(4), 838-857 (2008).
104. Ekins S, Kholodovych V, Ai N et al. Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol. Pharmacol. 74(3), 662-672 (2008).
105. Huang H, Wang H, Sinz M et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26(2), 258-268 (2007).
106. Xu HE, Stanley TB, Montana VG et al. Structural basis for antagonist-Mediated recruitment of nuclear co-Repressors by PPARalpha. Nature 415(6873), 813-817 (2002).
107. Kainuma M, Makishima M, Hashimoto Y, Miyachi H. Design, synthesis, and evaluation of non-Steroidal farnesoid X receptor (FXR) antagonist. Bioorg. Med. Chem. 15(7), 2587-2600 (2007).
108. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-Activators mediates binding to nuclear receptors. Nature 387(6634), 733-736 (1997).
109. Nolte RT, Wisely GB, Westin S et al. Ligand binding and co-Activator assembly of the peroxisome proliferator-Activated receptor-Gamma. Nature 395(6698), 137-143 (1998).
110. Westin S, Kurokawa R, Nolte RT et al. Interactions controlling the assembly of nuclear-Receptor heterodimers and co-Activators. Nature 395(6698), 199-202 (1998).
111. Geistlinger TR, Guy RK. An inhibitor of the interaction of thyroid hormone receptor beta and glucocorticoid interacting protein 1. J. Am. Chem. Soc. 123(7), 1525-1526 (2001).
112. Geistlinger TR, Guy RK. Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. J. Am. Chem. Soc. 125(23), 6852-6853 (2003).
113. Leduc AM, Trent JO, Wittliff JL et al. Helix-Stabilized cyclic peptides as selective inhibitors of steroid receptor-Coactivator interactions. Proc. Natl Acad. Sci. USA 100(20), 11273-11278 (2003).
114. Galande AK, Bramlett KS, Burris TP, Wittliff JL, Spatola AF. Thioether side chain cyclization for helical peptide formation. inhibitors of estrogen receptor-Coactivator interactions. J. Pept. Res. 63(3), 297-302 (2004).
115. Paige LA, Christensen DJ, Gron H et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc. Natl Acad. Sci. USA 96(7), 3999-4004 (1999).
116. Yang J, Chang CY, Safi R et al. Identification of ligand-Selective peptide antagonists of the mineralocorticoid receptor using phage display. Mol. Endocrinol. 25(1), 32-43
117. Mita Y, Dodo K, Noguchi-Yachide T et al. LXXLL peptide mimetics as inhibitors of the interaction of vitamin D receptor with coactivators. Bioorg. Med. Chem. Lett. 20(5), 1712-1717 (2010).
118. Mettu NB, Stanley TB, Dwyer MA et al. The nuclear receptor-Coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-Activated receptors. Mol. Endocrinol. 21(10), 2361-2377 (2007).
119. Pike JW, Pathrose P, Barmina O et al. Synthetic LXXLL peptide antagonize 1,25-Dihydroxyvitamin D3-Dependent transcription. J. Cell. Biochem. 88(2), 252-258 (2003).
120. Norris JD, Paige LA, Christensen DJ et al. Peptide antagonists of the human estrogen receptor. Science 285(5428), 744-746 (1999).
121. Kay BK, Kurakin AV, Hyde-Deruyscher R. From peptides to drugs via phage display. Drug Discov. Today 3(8), 370-378 (1998).
122. Sparks AB, Hoffman NG, Mcconnell SJ, Fowlkes DM, Kay BK. Cloning of ligand targets. Systematic isolation of SH3 domain-Containing proteins. Nat. Biotechnol. 14(6), 741-744 (1996).
123. Hall JM, Chang CY, Mcdonnell DP. Development of peptide antagonists that target estrogen receptor beta-Coactivator interactions. Mol. Endocrinol. 14(12), 2010-2023 (2000).
124. Galande AK, Bramlett KS, Trent JO, Burris TP, Wittliff JL, Spatola AF. Potent inhibitors of LXXLL-Based protein-Protein interactions. Chembiochem 6(11), 1991-1998 (2005).
125. Zella LA, Chang CY, Mcdonnell DP, Wesley Pike J. The vitamin D receptor interacts preferentially with DRIP205-like LxxLL motifs. Arch. Biochem. Biophys. 460(2), 206-212 (2007).
126. He B, Kemppainen JA, Wilson EM. FXXLF and WXXLF sequences mediate the NH2- terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 275(30), 22986-22994 (2000).
127. He B, Wilson EM. Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs. Mol. Cell. Biol. 23(6), 2135-2150 (2003).
128. Hur E, Pfaff SJ, Payne ES, Gron H, Buehrer BM, Fletterick RJ. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS ONE 2(9), E274 (2004).
129. Chang CY, Abdo J, Hartney T, Mcdonnell DP. Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol. Endocrinol. 19(10), 2478-2490 (2005).
130. Ozers Ms, Marks Bd, Gowda K et al. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-Type androgen receptor in a time-Resolved fluorescence resonance energy transfer assay. Biochemistry 46(3), 683-695 (2007).
131. Quayle SN, Mawji NR, Wang J, Sadar MD. Androgen receptor decoy molecules block the growth of prostate cancer. Proc. Natl Acad. Sci. USA 104(4), 1331-1336 (2007).
132. Narayanan R, Yepuru M, Szafran AT et al. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer. Cancer Res. 70(2), 842-851
133. Tran C, Ouk S, Clegg NJ et al. Development of a second-Generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009).
134. Carraz M, Zwart W, Phan T, Michalides R, Brunsveld L. Perturbation of estrogen receptor alpha localization with synthetic nona-Arginine LXXLL-Peptide coactivator binding inhibitors. Chem. Biol. 16(7), 702-711 (2009).
135. Tunnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F, Cardoso MC. Cargo-Dependent mode of uptake and bioavailability of TAT-Containing proteins and peptides in living cells. FASEB J. 20(11), 1775-1784 (2006).
136. Wang LH, Yang XY, Zhang X et al. Disruption of estrogen receptor DNA-Binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 10(6), 487-499 (2006
137. Kim HJ, Kim JY, Meng Z et al. 15-Deoxy-Delta12,14-Prostaglandin J2 inhibits transcriptional activity of estrogen receptor-Alpha via covalent modification of DNA-Binding domain. Cancer Res. 67(6), 2595-2602 (2007).
138. Mao C, Patterson NM, Cherian MT et al. A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-Dependent growth of cancer cells. J. Biol. Chem. 283(19), 12819-12830 (2008).
139. Olenyuk BZ, Zhang GJ, Klco JM, Nickols NG, Kaelin WG Jr, Dervan PB. Inhibition of vascular endothelial growth factor with a sequence-Specific hypoxia response element antagonist. Proc. Natl Acad. Sci. USA 101(48), 16768-16773 (2004).
140. Nickols NG, Jacobs CS, Farkas ME, Dervan PB. Improved nuclear localization of DNA-Binding polyamides. Nucleic Acids Res. 35(2), 363-370 (2007).
141. Hsu CF, Phillips JW, Trauger JW et al. Completion of a programmable DNA-Binding small molecule library. Tetrahedron 63(27), 6146-6151 (2007).
142. Gearhart MD, Dickinson L, Ehley J et al. Inhibition of DNA binding by human estrogen-Related receptor 2 and estrogen receptor alpha with minor groove binding polyamides. Biochemistry 44(11), 4196-4203 (2005).
143. Nickols NG, Dervan PB. Suppression of androgen receptor-Mediated gene expression by a sequence-Specific DNA-Binding polyamide. Proc. Natl Acad. Sci. USA 104(25), 10418-10423 (2007).
144. Chenoweth DM, Harki DA, Phillips JW, Dose C, Dervan PB. Cyclic pyrrole-Imidazole polyamides targeted to the androgen response element. J. Am. Chem. Soc. 131(20), 7182-7188 (2009).
145. Deslypere JP, Young M, Wilson JD, Mcphaul MJ. Testosterone and 5 alpha-Dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol. Cell. Endocrinol. 88(1-3), 15-22 (1992).
146. Wilbert DM, Griffin JE, Wilson JD. Characterization of the cytosol androgen receptor of the human prostate. J. Clin. Endocrinol. Metab. 56(1), 113-120 (1983).
147. Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-Hydroxylase-C17,20-lyase). Potential agents for the treatment of prostatic cancer. J. Med. Chem. 38(13), 2463-2471 (1995).
148. Jarman M, Barrie SE, Llera JM. The 16,17-Double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-Pyridyl)androsta-5, 16-Dien-3beta-ol) and related steroidal inhibitors. J. Med. Chem. 41(27), 5375-5381 (1998).
149. Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-Resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26(28), 4563-4571 (2008).
150. Grigoryev DN, Long BJ, Njar VC, Brodie AH. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J. Steroid Biochem. Mol. Biol. 75(1), 1-10 (2000).
151. Kawamoto T, Mitsuuchi Y, Toda K et al. Role of steroid 11 beta-Hydroxylase and steroid 18-Hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc. Natl Acad. Sci. USA 89(4), 1458-1462 (1992).
152. Davila DF, Nunez TJ, Odreman R, De Davila CA. Mechanisms of neurohormonal activation in chronic congestive heart failure. pathophysiology and therapeutic implications. Int. J. Cardiol. 101(3), 343-346 (2005).
153. Brilla CG. Renin-Angiotensin-Aldosterone system and myocardial fibrosis. Cardiovasc. Res. 47(1), 1-3 (2000).
154. Fiebeler A, Nussberger J, Shagdarsuren E et al. Aldosterone synthase inhibitor ameliorates angiotensin II-Induced organ damage. Circulation 111(23), 3087-3094 (2005).
155. Mulder P, Mellin V, Favre J et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure. A comparison with spironolactone. Eur. Heart J. 29(17), 2171-2179 (2008).
156. Huang BS, White RA, Ahmad M, Tan J, Jeng AY, Leenen FH. Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction. Cardiovasc. Res. 81(3), 574-581 (2009).
157. Gamliel-Lazarovich A, Gantman A, Coleman R, Jeng AY, Kaplan M, Keidar S. FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-Deficient mice. J. Hypertens. 28(9), 1900-1907
158. Ulmschneider S, Muller-Vieira U, Mitrenga M et al. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes. Potent inhibitors of aldosterone synthase. J. Med. Chem. 48(6), 1796-1805 (2005).
159. Voets M, Antes I, Scherer C et al. Heteroaryl-Substituted naphthalenes and structurally modified derivatives. Selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J. Med. Chem. 48(21), 6632-6642 (2005).
160. Voets M, Antes I, Scherer C et al. Synthesis and evaluation of heteroaryl-Substituted dihydronaphthalenes and indenes. Potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J. Med. Chem. 49(7), 2222-2231 (2006).
161. Lucas S, Heim R, Ries C, Schewe KE, Birk B, Hartmann Rw. In vivo active aldosterone synthase inhibitors with improved selectivity. Lead optimization providing a series of pyridine substituted 3,4-Dihydro-1H-Quinolin-2-one derivatives. J. Med. Chem. 51(24), 8077-8087 (2008).
162. Lucas S, Negri M, Heim R, Zimmer C, Hartmann RW. Fine-Tuning the selectivity of aldosterone synthase inhibitors. Structure- activity and structure-Selectivity insights from studies of heteroaryl substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1-Ij]quinolin- 4-one derivatives. J. Med. Chem. 54(7), 2307-2319.
163. Han S, Li T, Ellis E, Strom S, Chiang JY. A novel bile acid-Activated vitamin D receptor signaling in human hepatocytes. Mol. Endocrinol. 24(6), 1151-1164 (2010).
164. Watanabe M, Houten SM, Mataki C et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439(7075), 484-489 (2006).
165. Da-Silva WS, Harney JW, Kim BW et al. The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. Diabetes 56(3), 767-776 (2007).
166. Hoeck W, Rusconi S, Groner B. Down-Regulation and phosphorylation of glucocorticoid receptors in cultured cells. Investigations with a monospecific antiserum against a bacterially expressed receptor fragment. J. Biol. Chem. 264(24), 14396-14402 (1989).
167. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-Activated protein kinase signals their degradation by the 26S proteasome. Proc. Natl Acad. Sci. USA 97(3), 1032-1037 (2000).
168. Nawaz Z, Lonard DM, Dennis AP, Smith Cl, O'Malley BW. Proteasome-Dependent degradation of the human estrogen receptor. Proc. Natl Acad. Sci. USA 96(5), 1858-1862 (1999).
169. Li XY, Boudjelal M, Xiao JH et al. 1,25-Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/ proteasome-Mediated degradation in human skin. Mol. Endocrinol. 13(10), 1686-1694 (1999).
170. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL, Chang C. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J. Biol. Chem. 277(39), 36570-36576 (2002).
171. Kretzer NM, Cherian MT, Mao C et al. A noncompetitive small molecule inhibitor of estrogen-Regulated gene expression and breast cancer cell growth that enhances proteasome-Dependent degradation of estrogen receptor {alpha}. J. Biol. Chem. 285(53), 41863-41873 (2010).
172. Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. miR-206 Expression is down-Regulated in estrogen receptor alpha-Positive human breast cancer. Cancer Res. 68(13), 5004-5008 (2008).
173. Vreugdenhil E, Verissimo CS, Mariman R et al. MicroRNA 18 and 124a down-Regulate the glucocorticoid receptor. Implications for glucocorticoid responsiveness in the brain. Endocrinology 150(5), 2220-2228 (2009).
174. Takagi S, Nakajima M, Mohri T, Yokoi T. Post-Transcriptional regulation
175. Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. Over-Expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett. 583(4), 759-766 (2009).
176. Choi JH, Banks AS, Estall JL et al. Anti-Diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466(7305), 451-456.
177. Acton III JJ, Black RM, Jones AB et al. Benzoyl 2-Methyl indoles as selective PPARgamma modulators. Bioorg. Med. Chem. Lett. 15(2), 357-362 (2005).
178. Choi JH, Banks AS, Kamenecka TM et al. Antidiabetic actions of a non-Agonist PPARg ligand blocking Cdk5-Mediated phosphorylation. Nature 477(7365), 477-481 (2011).
179. Smith DF, Toft DO. Minireview. the intersection of steroid receptors with molecular chaperones. observations and questions. Mol. Endocrinol. 22(10), 2229-2240 (2008).
180. Riggs DL, Roberts PJ, Chirillo SC et al. The Hsp90-Binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J. 22(5), 1158-1167 (2003).
181. Riggs DL, Cox MB, Tardif HL, Hessling M, Buchner J, Smith DF. Noncatalytic role of the FKBP52 peptidyl-Prolyl isomerase domain in the regulation of steroid hormone signaling. Mol. Cell. Biol. 27(24), 8658-8669 (2007).
182. De Leon JT, Iwai A, Feau C et al. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc. Natl Acad. Sci. USA 108(29), 11878-11883 (2011).
183. Andersen RJ, Mawji NR, Wang J et al. Regression of castrate-Recurrent prostate cancer by a small-Molecule inhibitor of the amino-Terminus domain of the androgen receptor. Cancer Cell 17(6), 535-546 (2010).
184. Gerber AN, Masuno K, Diamond MI. Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. Proc. Natl Acad. Sci. USA 106(12), 4929-4934 (2009).
185. Wang JC, Shah N, Pantoja C et al. Novel arylpyrazole compounds selectively modulate glucocorticoid receptor regulatory activity. Genes Dev. 20(6), 689-699 (2006).
186. Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill TG, O'Malley BW. Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol. Endocrinol. 25(12), 2041-2053 (2011).
187. Yoon JC, Puigserver P, Chen G et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413(6852), 131-138 (2001).
188. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435(7043), 834-838 (2005).
189. Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65(16), 7065-7070 (2005).
190. De Souza Rocha Simonini P, Breiling A, Gupta N et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 70(22), 9175-9184 (2010).
191. Ribas J, Ni X, Haffner M et al. miR-21. an androgen receptor-Regulated microRNA that promotes hormone-Dependent and hormone-Independent prostate cancer growth. Cancer Res. 69(18), 7165-7169 (2009).
192. Murata T, Takayama K, Katayama S et al. miR-148a is an androgen-Responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis. 13(4), 356-361.
193. Mcdermott AM, Heneghan HM, Miller N, Kerin MJ. The therapeutic potential of microRNAs. Disease modulators and drug targets. Pharm. Res. 28(12), 3016-3029.